Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05735184
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2023-02-09
Brief Title:
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With VenetoclaxAzacitidine Venetoclax or 73 in Patients With AML
Sponsor:
Kura Oncology Inc
Organization:
Kura Oncology Inc
Study Overview
Official Title:
Phase 1 Study of VenetoclaxAzacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction CytarabineDaunorubicin 73 Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase 1 study will assess the safety tolerability and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine venaza ven and 73 for two different molecularly-defined arms NPM1-m and KMT2A-r
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None